Lowenstein client Sonnet BioTherapeutics, Inc. (Nasdaq: SONN) has closed its merger with Chanticleer Holdings, Inc. to form a company operating under the name Sonnet BioTherapeutics Holdings, Inc. (Sonnet), with its shares trading on the Nasdaq Capital Market under the ticker symbol “SONN”. Sonnet is a biopharmaceutical company developing innovative, targeted biologic drugs with enhanced single or bispecific mechanisms of action.
Immediately prior to the merger, Sonnet completed a private placement financing resulting in gross proceeds of $19 million and completed its acquisition of the global development rights for Atexakin Alfa from Relief Therapeutics SA., while the public entity spun off its restaurant operations to Amergent Hospitality Group, Inc.
The merger agreement was originally announced in October 2019. The deal team included Steven M. Skolnick, Alan Wovsaniker, Brian A. Silikovitz, Alexander Dinur, Tracy F. Buffer, and Madeline Roe.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.
